The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
Medicines for Europe welcomes the European Parliament’s adoption of its report on ‘Options for improving access to medicines’ that places generic, biosimilar and value added medicines at the heart of the debate on access to medicines.
Тhe European Commission (EC) and the US Food and Drug Administration have reached an agreement which will enable EU and FDA to avoid the duplication of inspections of medicines manufacturing facilities in the two regions.
The EU Member States' authorities will recognise inspections made by US authorities, and vice versa.
